Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and mechanistic tissue study (CEBM Level 5: bench/animal research)
PubMed 33771213 · doi:10.1186/s13073-021-00863-5
What was done
The authors evaluated PGC-1α expression in microglia from human and mouse brain tissues following ischemic stroke. They then subjected transgenic mice with microglia-specific PGC-1α overexpression to middle cerebral artery occlusion (MCAO) and evaluated microglial morphology, gene expression profiles, inflammatory cytokine production, and NLRP3 inflammasome activation. Mechanistic pathways were examined using ChIP-seq, immunofluorescence for autophagy and mitophagy flux, and ULK1 pharmacological inhibition or genetic knockdown.
What was found
The abstract reports no numerical values, confidence intervals, or exact effect sizes. PGC-1α expression was transiently increased after ischemic stroke in both human and mouse brain samples. Microglia-specific PGC-1α overexpressing mice showed decreased neurological deficits, reduced NLRP3 activation, and lower proinflammatory cytokine production alongside enhanced autophagy and mitophagy via ULK1. Inhibition or knockdown of ULK1 abolished these neuroprotective effects.
Why it matters
This study outlines a cellular mechanism wherein microglial PGC-1α promotes ULK1-mediated mitophagy to suppress post-ischemic neuroinflammation, highlighting a potential preclinical target for acute ischemic stroke therapy.
Limits
The abstract provides no sample sizes or quantitative metrics. The study relies primarily on a mouse occlusion model and in vitro assays, which may not directly replicate human stroke physiology or clinical therapeutic windows.
Cited by
- supports PGC-1alpha promotes mitochondrial biogenesis and enhances cellular energy metabolism across the body, including in microglial cells.